MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, AKRO had -$44,417K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$44,417K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of shor...
    • Stock-based compensation expense
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchase of short-term and long-...
    • Repayment of loan payable
    • Others

Cash Flow
2025-09-30
2025-06-30
Net loss
-81,566 -141,230
Stock-based compensation expense
9,261 17,839
Non-cash lease expense
69 134
Net amortization of premiums and discounts on marketable securities
2,429 5,323
Amortization of debt issuance costs and discount
179 364
Unrealized foreign exchange gain and loss
--26
Loss on extinguishment of loan payable
-1,557 -
Fair value change in warrant liability
-400 206
Prepaid expenses and other assets
-5,489 -5,104
Accounts payable
7,176 4,203
Accrued expenses and other current liabilities
-6,408 2,908
Operating lease liability
-73 -141
Net cash used in operating activities
-67,171 -115,910
Purchase of short-term and long-term marketable securities
73,496 658,977
Proceeds from maturities of short-term marketable securities
130,277 256,134
Net cash (used in) investing activities
56,781 -402,843
Proceeds from the exercise of stock options
3,371 10,371
Proceeds from the issuance of common stock pursuant to employee stock purchase plan purchases
0 458
Proceeds from the issuance of common stock and pre-funded warrants in a follow-on public offering
0 378,350
Proceeds from the issuance of common stock pursuant to the atm offering
0 10,361
Repayment of loan payable
37,398 -
Payment of debt and equity issuance costs
0 576
Net cash provided by financing activities
-34,027 398,964
Net (decrease) increase in cash and cash equivalents
-44,417 -119,789
Cash and cash equivalents at beginning of period
340,238 -
Cash and cash equivalents at end of period
176,032 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof short-term...$130,277K Net cash (used in)investing activities$56,781K Canceled cashflow$73,496K Net (decrease)increase in cash and cash...-$44,417K Canceled cashflow$56,781K Stock-based compensationexpense$9,261K Accounts payable$7,176K Prepaid expenses andother assets-$5,489K Loss onextinguishment of loan payable-$1,557K Amortization of debt issuancecosts and discount$179K Non-cash lease expense$69K Proceeds from theexercise of stock options$3,371K Purchase of short-termand long-term...$73,496K Net cash used inoperating activities-$67,171K Canceled cashflow$23,731K Net cash provided byfinancing activities-$34,027K Canceled cashflow$3,371K Net loss-$81,566K Accrued expenses andother current...-$6,408K Net amortization ofpremiums and discounts on...$2,429K Fair value change inwarrant liability-$400K Operating lease liability-$73K Repayment of loan payable$37,398K

Akero Therapeutics, Inc. (AKRO)

Akero Therapeutics, Inc. (AKRO)